148 related articles for article (PubMed ID: 34565600)
1. Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data.
Ataseven B; Tripon D; Schwameis R; Harter P; Rhiem K; Schneider S; Heikaus S; Baert T; Francesco AP; Heitz F; Traut A; Groeben HT; Schmutzler R; du Bois A
Gynecol Oncol; 2021 Dec; 163(3):569-577. PubMed ID: 34565600
[TBL] [Abstract][Full Text] [Related]
2. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA
Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802
[TBL] [Abstract][Full Text] [Related]
3. The first Japanese nationwide multicenter study of
Enomoto T; Aoki D; Hattori K; Jinushi M; Kigawa J; Takeshima N; Tsuda H; Watanabe Y; Yoshihara K; Sugiyama T
Int J Gynecol Cancer; 2019 Jul; 29(6):1043-1049. PubMed ID: 31263023
[TBL] [Abstract][Full Text] [Related]
4. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
5. Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
Cancer Res Treat; 2020 Oct; 52(4):1229-1241. PubMed ID: 32718143
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM
Gynecol Oncol; 2020 Feb; 156(2):377-386. PubMed ID: 31753525
[TBL] [Abstract][Full Text] [Related]
7. Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer.
Shi T; Wang P; Tang W; Jiang R; Yin S; Shi D; Wang Q; Wei Q; Zang R
Cell Physiol Biochem; 2018; 47(5):2088-2096. PubMed ID: 29975922
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.
Paik ES; Heo EJ; Choi CH; Kim JH; Kim JW; Kim YM; Park SY; Lee JW; Kim JW; Kim BG
Cancer Sci; 2021 Dec; 112(12):5055-5067. PubMed ID: 34657357
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
Tsibulak I; Wieser V; Degasper C; Shivalingaiah G; Wenzel S; Sprung S; Lax SF; Marth C; Fiegl H; Zeimet AG
Br J Cancer; 2018 Sep; 119(6):683-692. PubMed ID: 30111871
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.
De Nonneville A; Zemmour C; Frank S; Joly F; Ray-Coquard I; Costaz H; Classe JM; Floquet A; De la Motte Rouge T; Colombo PE; Sauterey B; Leblanc E; Pomel C; Marchal F; Barranger E; Savoye AM; Guillemet C; Petit T; Pautier P; Rouzier R; Gladieff L; Simon G; Courtinard C; Sabatier R
Gynecol Oncol; 2021 Oct; 163(1):64-71. PubMed ID: 34294414
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases.
Gallotta V; Conte C; D'Indinosante M; Capoluongo E; Minucci A; De Rose AM; Ardito F; Giuliante F; Di Giorgio A; Zannoni GF; Fagotti A; Margreiter C; Scambia G; Ferrandina G
Eur J Surg Oncol; 2019 Nov; 45(11):2096-2102. PubMed ID: 31227342
[TBL] [Abstract][Full Text] [Related]
12. Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands.
Vencken PM; Reitsma W; Kriege M; Mourits MJ; de Bock GH; de Hullu JA; van Altena AM; Gaarenstroom KN; Vasen HF; Adank MA; Schmidt MK; van Beurden M; Zweemer RP; Rijcken F; Slangen BF; Burger CW; Seynaeve C
Ann Oncol; 2013 Aug; 24(8):2036-42. PubMed ID: 23543211
[TBL] [Abstract][Full Text] [Related]
13. BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?
Morgan RD; Burghel GJ; Flaum N; Bulman M; Smith P; Clamp AR; Hasan J; Mitchell CL; Salih Z; Woodward ER; Lalloo F; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
Br J Cancer; 2022 Jul; 127(1):163-167. PubMed ID: 35260807
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
Engel C; Rhiem K; Hahnen E; Loibl S; Weber KE; Seiler S; Zachariae S; Hauke J; Wappenschmidt B; Waha A; Blümcke B; Kiechle M; Meindl A; Niederacher D; Bartram CR; Speiser D; Schlegelberger B; Arnold N; Wieacker P; Leinert E; Gehrig A; Briest S; Kast K; Riess O; Emons G; Weber BHF; Engel J; Schmutzler RK;
BMC Cancer; 2018 Mar; 18(1):265. PubMed ID: 29514593
[TBL] [Abstract][Full Text] [Related]
15. The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.
Sun C; Li N; Ding D; Weng D; Meng L; Chen G; Ma D
PLoS One; 2014; 9(5):e95285. PubMed ID: 24788697
[TBL] [Abstract][Full Text] [Related]
16. Predicting the likelihood of a
Morgan RD; Burghel GJ; Flaum N; Bulman M; Smith P; Clamp AR; Hasan J; Mitchell C; Salih Z; Woodward ER; Lalloo F; Shaw J; Desai S; Crosbie EJ; Edmondson RJ; Schlecht H; Wallace AJ; Jayson GC; Evans DGR
J Clin Pathol; 2023 Oct; 76(10):684-689. PubMed ID: 35738887
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models.
Eoh KJ; Chung YS; Lee SH; Park SA; Kim HJ; Yang W; Lee IO; Lee JY; Cho H; Chay DB; Kim S; Kim SW; Kim JH; Kim YT; Nam EJ
Cancer Res Treat; 2018 Jul; 50(3):956-963. PubMed ID: 29059719
[TBL] [Abstract][Full Text] [Related]
18. The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.
Kim SR; Malcolmson J; Li X; Bernardini MQ; Hogen L; May T
Gynecol Oncol; 2021 Sep; 162(3):702-706. PubMed ID: 34256977
[TBL] [Abstract][Full Text] [Related]
19. Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
Singer CF; Tan YY; Muhr D; Rappaport C; Gschwantler-Kaulich D; Grimm C; Polterauer S; Pfeiler G; Berger A; Tea MM
Cancer Med; 2019 Apr; 8(4):1875-1881. PubMed ID: 30821131
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of Pathogenic Germline
Abe A; Imoto I; Tange S; Nishimura M; Iwasa T
Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
